Skip to main content
. Author manuscript; available in PMC: 2011 Mar 16.
Published in final edited form as: Lancet Oncol. 2009 Dec 10;11(1):55–65. doi: 10.1016/S1470-2045(09)70314-6

Figure 3.

Figure 3

Primary disease-free survival endpoint by treatment and Recurrence Score (RS) groups. The log-rank tests are stratified by number of positive nodes. Panel A shows disease-free survival by treatment (CAF followed by tamoxifen versus tamoxifen alone) overall, and Panels B–D depicts the outcomes within each RS risk group of low, intermediate, and high, respectively.